157 related articles for article (PubMed ID: 36375678)
1. Cost-Effectiveness of Venetoclax Plus Obinutuzumab Versus Chlorambucil Plus Obinutuzumab for the First-Line Treatment of Adult Patients With Chronic Lymphocytic Leukemia: An Extended Societal View.
Do N; Thielen FW
Value Health; 2023 Apr; 26(4):477-486. PubMed ID: 36375678
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United States.
Chatterjee A; Shapouri S; Manzoor BS; Ravelo A; Sail K; Qendri V; van de Wetering G; Davids MS
J Manag Care Spec Pharm; 2021 Nov; 27(11):1532-1544. PubMed ID: 34714110
[No Abstract] [Full Text] [Related]
3. Cost-effectiveness of First-line Chronic Lymphocytic Leukemia Treatments When Full-dose Fludarabine Is Unsuitable.
Soini E; Hautala A; Poikonen E; Becker U; Kyttälä M; Martikainen J
Clin Ther; 2016 Apr; 38(4):889-904.e14. PubMed ID: 26970696
[TBL] [Abstract][Full Text] [Related]
4. Cost-utility analysis of venetoclax in combination with obinutuzumab as first-line treatment of chronic lymphocytic leukaemia in Spain.
Moreno-Martínez E; De la Serna-Torroba J; Escudero-Vilaplana V; Hernández-Rivas JÁ; Sánchez-Cuervo M; Sánchez-Hernández R
Farm Hosp; 2022 Apr; 46(3):121-132. PubMed ID: 36183205
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of acalabrutinib regimens in treatment-naïve chronic lymphocytic leukemia in the United States.
Munir T; Genovez V; Genestier V; Ryan K; Liljas B; Gaitonde P
Expert Rev Pharmacoecon Outcomes Res; 2023 Jun; 23(5):579-589. PubMed ID: 36987886
[TBL] [Abstract][Full Text] [Related]
6. A Probabilistic Cost-Effectiveness Analysis of Venetoclax and Obinutuzumab as a First-Line Therapy in Chronic Lymphocytic Leukemia in Canada.
Chatterjee A; van de Wetering G; Goeree R; Owen C; Desbois AM; Barakat S; Manzoor BS; Sail K
Pharmacoecon Open; 2023 Mar; 7(2):199-216. PubMed ID: 36334238
[TBL] [Abstract][Full Text] [Related]
7. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial.
Al-Sawaf O; Zhang C; Tandon M; Sinha A; Fink AM; Robrecht S; Samoylova O; Liberati AM; Pinilla-Ibarz J; Opat S; Sivcheva L; Le Dû K; Fogliatto LM; Niemann CU; Weinkove R; Robinson S; Kipps TJ; Tausch E; Schary W; Ritgen M; Wendtner CM; Kreuzer KA; Eichhorst B; Stilgenbauer S; Hallek M; Fischer K
Lancet Oncol; 2020 Sep; 21(9):1188-1200. PubMed ID: 32888452
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of targeted treatment vs chemoimmunotherapy in treatment-naive unfit CLL without TP53 aberrations.
Slot M; Niemann CU; Ehlers LH; Rotbain EC
Blood Adv; 2023 Aug; 7(15):4186-4196. PubMed ID: 37184985
[TBL] [Abstract][Full Text] [Related]
9. Cost Effectiveness of Ofatumumab Plus Chlorambucil in First-Line Chronic Lymphocytic Leukaemia in Canada.
Herring W; Pearson I; Purser M; Nakhaipour HR; Haiderali A; Wolowacz S; Jayasundara K
Pharmacoeconomics; 2016 Jan; 34(1):77-90. PubMed ID: 26518293
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of obinutuzumab for chronic lymphocytic leukaemia in The Netherlands.
Blommestein HM; de Groot S; Aarts MJ; Vemer P; de Vries R; van Abeelen AF; Posthuma EF; Uyl-de Groot CA
Leuk Res; 2016 Nov; 50():37-45. PubMed ID: 27657652
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness and Economic Burden Analyses on All First-Line Treatments of Chronic Lymphocytic Leukemia.
Alrawashdh N; McBride A; Erstad B; Sweasy J; Persky DO; Abraham I
Value Health; 2022 Oct; 25(10):1685-1695. PubMed ID: 35537984
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness Model for Chemoimmunotherapy Options in Patients with Previously Untreated Chronic Lymphocytic Leukemia Unsuitable for Full-Dose Fludarabine-Based Therapy.
Becker U; Briggs AH; Moreno SG; Ray JA; Ngo P; Samanta K
Value Health; 2016 Jun; 19(4):374-82. PubMed ID: 27325329
[TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness of Ibrutinib Compared With Obinutuzumab With Chlorambucil in Untreated Chronic Lymphocytic Leukemia Patients With Comorbidities in the United Kingdom.
Sinha R; Redekop WK
Clin Lymphoma Myeloma Leuk; 2018 Feb; 18(2):e131-e142. PubMed ID: 29398648
[TBL] [Abstract][Full Text] [Related]
14. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.
Fischer K; Al-Sawaf O; Bahlo J; Fink AM; Tandon M; Dixon M; Robrecht S; Warburton S; Humphrey K; Samoylova O; Liberati AM; Pinilla-Ibarz J; Opat S; Sivcheva L; Le Dû K; Fogliatto LM; Niemann CU; Weinkove R; Robinson S; Kipps TJ; Boettcher S; Tausch E; Humerickhouse R; Eichhorst B; Wendtner CM; Langerak AW; Kreuzer KA; Ritgen M; Goede V; Stilgenbauer S; Mobasher M; Hallek M
N Engl J Med; 2019 Jun; 380(23):2225-2236. PubMed ID: 31166681
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of Anti-CD19 chimeric antigen receptor T-Cell therapy in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia. A societal view.
Thielen FW; van Dongen-Leunis A; Arons AMM; Ladestein JR; Hoogerbrugge PM; Uyl-de Groot CA
Eur J Haematol; 2020 Aug; 105(2):203-215. PubMed ID: 32289184
[TBL] [Abstract][Full Text] [Related]
16. Economic evaluation of obinutuzumab in combination with chlorambucil in first-line treatment of patients with chronic lymphocytic leukemia in Spain.
Casado LF; Burgos A; González-Haba E; Loscertales J; Krivasi T; Orofino J; Rubio-Terres C; Rubio-Rodríguez D
Clinicoecon Outcomes Res; 2016; 8():475-484. PubMed ID: 27703384
[TBL] [Abstract][Full Text] [Related]
17. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.
Moreno C; Greil R; Demirkan F; Tedeschi A; Anz B; Larratt L; Simkovic M; Samoilova O; Novak J; Ben-Yehuda D; Strugov V; Gill D; Gribben JG; Hsu E; Lih CJ; Zhou C; Clow F; James DF; Styles L; Flinn IW
Lancet Oncol; 2019 Jan; 20(1):43-56. PubMed ID: 30522969
[TBL] [Abstract][Full Text] [Related]
18. The clinical effectiveness and cost-effectiveness of rituximab for the first-line treatment of chronic lymphocytic leukaemia: an evidence review of the submission from Roche.
Main C; Pitt M; Moxham T; Stein K
Health Technol Assess; 2010 Oct; 14(Suppl. 2):27-32. PubMed ID: 21047488
[TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States.
Shah BD; Smith NJ; Feng C; Jeyakumar S; Castaigne JG; Faghmous I; Masouleh BK; Malone DC; Bishop MR
Adv Ther; 2022 Aug; 39(8):3678-3695. PubMed ID: 35727476
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and Exposure-Response Analysis of Venetoclax + Obinutuzumab in Chronic Lymphocytic Leukemia: Phase 1b Study and Phase 3 CLL14 Trial.
Samineni D; Gibiansky L; Wang B; Vadhavkar S; Rajwanshi R; Tandon M; Sinha A; Al-Sawaf O; Fischer K; Hallek M; Salem AH; Li C; Miles D
Adv Ther; 2022 Aug; 39(8):3635-3653. PubMed ID: 35708885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
